“…The contribution of NEAT1 to cancer progression has also been studied in other cancers, including cervical cancer [ 77 ], cholangiocarcinoma [ 78 ], endometrial cancer [ 79 ], esophageal carcinoma [ 80 ], gallbladder cancer [ 81 ], glioblastoma [ 82 ], Hodgkin’s lymphoma [ 83 ], laryngeal carcinoma [ 84 ], melanoma [ 85 ], multiple myeloma [ 11 ], nasopharyngeal carcinoma [ 86 ], osteosarcoma [ 87 ], pancreatic carcinoma [ 88 ], retinoblastoma [ 89 ], thyroid cancer [ 90 ], and tongue carcinoma [ 91 ]. In those cancers, NEAT1 plays a pro-proliferative role and promotes the progression of cancer by upregulating the expression of some oncogenes or downregulating the expression of some tumor suppressor genes.…”